10+ years
of clinical experience

in dermatology2

More than

250000 patients

patients have been prescribed HUMIRA for plaque psoriasis since its FDA approval in 2008.3,4

moderate to severe chronic plaque psoriasis (Ps)

MODERATE TO SEVERE CHRONIC

PLAQUE PSORIASIS (Ps)

More than 250,000 patients have been prescribed HUMIRA for Ps since its FDA approval in 2008.3,4

active psoriatic arthritis (PsA)

ACTIVE

PSORIATIC ARTHRITIS (PsA)

An every-other-week dosing schedule, with no loading dose.1

moderate to severe chronic hidradenitis suppurativa (HS)

MODERATE TO SEVERE

HIDRADENITIS SUPPURATIVA (HS)

More than 15,000 patients have been prescribed HUMIRA for HS since its FDA approval in 2015.5

Dramatic skin clearance in Ps

HUMIRA clinical data includes dramatic skin clearance at 16 weeks for most patients and a well-studied safety profile in moderate to severe Ps.1,6-10

>>> CSS OVERRIDE
#1 prescribed biologic by dermatologists & rheumatologists

Powerful protection against further joint damage

HUMIRA clinical data includes inhibition of radiographic progression at week 48 vs placebo at week 24 and improvement of signs and symptoms at week 12 in many patients.1

In 2019, over

97%

of National Commercial, Medicare Part D, and Medicaid patients have access to HUMIRA as a preferred, first-line targeted immunomodulator (TIM) on formulary.11

Formulary Definitions: Preferred/Step 1 means the product is placed on the plan's preferred formulary. Non-preferred products require a higher out-of-pocket cost or step edit, or are placed on a higher tier. First-line refers to a preferred or parity formulary status.

HUMIRA COMPLETE logo

Resources to help your patients start and stay on track with their treatment plan.

First & only FDA approved treatment for moderate to severe hidradenitis suppurativa

The 1st and only FDA-approved treatment for HS

Only HUMIRA is FDA-approved to provide clinically meaningful improvement in moderate to severe HS.1,12

*Based on IMS NPA data: total prescriptions written by Dermatologists and Rheumatologists 6/2016-11/2018 vs ACTEMRA®, CIMZIA®, COSENTYX®, ENBREL®, ILUMYA®, KEVZARA®, KINERET®, OLUMIANT®, ORENCIA®, OTEZLA®, SILIQ®, SIMPONI®, STELARA®, TALTZ®, TREMFYA®, and XELJANZ®. All trademarks are properties of their respective owners.